Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Low PE Investor model based on the published ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options begin trading today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks. In his second appearance on Squawk on the Street after the ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks Jim Cramer recently talked about. The Federal Reserve ...

Despite high valuation risks, VRTX's innovative CF treatments and diversified pipeline make it a compelling long-term investment opportunity. Vertex stock has lagged the market since then ...

NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") ...

Barclays analyst Gena Wang maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $418.00. The company’s shares opened today at $395.72.

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other healthcare stocks Jim Cramer has made bold predictions about.